Clinimetric methods for evaluating patients with Parkinson's disease in the context of the latest treatment strategies
DOI:
https://doi.org/10.12775/JEHS.2023.13.04.031Keywords
Parkinson's disease, clinimetric assessment, rating scales, new treatmentsAbstract
Background: Parkinson's disease is a neurodegenerative disease involving the deposition of alpha-synuclein deposits in dopaminergic neurons of the black matter, resulting in a decrease in dopamine levels in the central nervous system and the development of motor and non-motor symptoms. Aim of the study: This study aims to identify clinimetric methods for evaluating patients with Parkinson's disease in the context of contemporary therapies. Material and methods: English-language scientific literature from 2012 - 2022 from databases such as PubMed, SCOPUS, Web of Science, Google Scholar was reviewed. Searches were conducted according to keywords: Parkinson's disease, clinical evaluation, and treatment methods. 69 items of literature were qualified for analysis. Results and conclusions: The diagnosis of Parkinson's disease is a diagnosis by exclusion, there are no available and inexpensive methods to diagnose the disease with certainty. The clinimetric assessment of the patient is therefore the basis not only for diagnosis but also for effective, tailored treatment. There are many assessment tools dedicated to patients with this disease entity, and these are the ones recommended for this process. Contemporary treatment methods, especially for those in whom the effectiveness of pharmacological treatment is unsatisfactory, include deep brain stimulation, enteral infusion of DuoDopa®, and subcutaneous infusion/injections of apomorphine. The inclusion of the techniques depends mainly on the assessed condition of the patient.
References
J. D. GAZEWOOD, D. R. RICHARDS, and K. CLEBAK, “Parkinson Disease: An Update,” Am Fam Physician, vol. 87, no. 4, pp. 267–273, Feb. 2013, Accessed: Feb. 19, 2023. [Online]. Available: https://www.aafp.org/pubs/afp/issues/2013/0215/p267.html
R. Balestrino and A. H. V. Schapira, “Parkinson disease,” Eur J Neurol, vol. 27, no. 1, pp. 27–42, Jan. 2020, doi: 10.1111/ENE.14108.
W. Poewe et al., “Parkinson disease,” Nature Reviews Disease Primers 2017 3:1, vol. 3, no. 1, pp. 1–21, Mar. 2017, doi: 10.1038/nrdp.2017.13.
L. v. Kalia and A. E. Lang, “Parkinson’s disease,” The Lancet, vol. 386, no. 9996, pp. 896–912, Aug. 2015, doi: 10.1016/S0140-6736(14)61393-3.
J. P. Chippaux, Z. Saz-Parkinson, and J. M. Amate Blanco, “Epidemiology of snakebite in Europe: Comparison of data from the literature and case reporting,” Toxicon, vol. 76, pp. 206–213, Dec. 2013, doi: 10.1016/J.TOXICON.2013.10.004.
A. Ascherio and M. A. Schwarzschild, “The epidemiology of Parkinson’s disease: risk factors and prevention,” Lancet Neurol, vol. 15, no. 12, pp. 1257–1272, Nov. 2016, doi: 10.1016/S1474-4422(16)30230-7.
A. Elbaz, L. Carcaillon, S. Kab, and F. Moisan, “Epidemiology of Parkinson’s disease,” Rev Neurol (Paris), vol. 172, no. 1, pp. 14–26, Jan. 2016, doi: 10.1016/J.NEUROL.2015.09.012.
J. Meara and P. Hobson, “Epidemiology of Parkinson’s disease,” Parkinson’s Disease in the Older Patient, Second Edition, pp. 30–38, Jan. 2018, doi: 10.1201/9781315365428-3/EPIDEMIOLOGY-PARKINSON-DISEASE-JOLYON-MEARA-PETER-HOBSON.
G. DeMaagd and A. Philip, “Parkinson’s Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis,” Pharmacy and Therapeutics, vol. 40, no. 8, p. 504, Aug. 2015, Accessed: Feb. 19, 2023. [Online]. Available: /pmc/articles/PMC4517533/
M. Hallett, “Parkinson’s disease tremor: pathophysiology,” Parkinsonism Relat Disord, vol. 18, no. SUPPL. 1, pp. S85–S86, Jan. 2012, doi: 10.1016/S1353-8020(11)70027-X.
A. Oswal, P. Brown, and V. Litvak, “Synchronized neural oscillations and the pathophysiology of Parkinson’s disease,” Curr Opin Neurol, vol. 26, no. 6, pp. 662–670, Dec. 2013, doi: 10.1097/WCO.0000000000000034.
L. M. Collins, A. Toulouse, T. J. Connor, and Y. M. Nolan, “Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease,” Neuropharmacology, vol. 62, no. 7, pp. 2154–2168, Jun. 2012, doi: 10.1016/J.NEUROPHARM.2012.01.028.
R. de La Fuente-Fernández, “Role of DaTSCAN and clinical diagnosis in Parkinson disease,” Neurology, vol. 78, no. 10, pp. 696–701, Mar. 2012, doi: 10.1212/WNL.0B013E318248E520.
P. R. Magesh, R. D. Myloth, and R. J. Tom, “An Explainable Machine Learning Model for Early Detection of Parkinson’s Disease using LIME on DaTSCAN Imagery,” Comput Biol Med, vol. 126, p. 104041, Nov. 2020, doi: 10.1016/J.COMPBIOMED.2020.104041.
J. Massano and K. P. Bhatia, “Clinical Approach to Parkinson’s Disease: Features, Diagnosis, and Principles of Management,” Cold Spring Harb Perspect Med, vol. 2, no. 6, p. a008870, Jun. 2012, doi: 10.1101/CSHPERSPECT.A008870.
K. L. Adams-Carr, J. P. Bestwick, S. Shribman, A. Lees, A. Schrag, and A. J. Noyce, “Constipation preceding Parkinson’s disease: a systematic review and meta-analysis,” J Neurol Neurosurg Psychiatry, vol. 87, no. 7, pp. 710–716, Jul. 2016, doi: 10.1136/JNNP-2015-311680.
B. Heim, F. Krismer, R. de Marzi, and K. Seppi, “Magnetic resonance imaging for the diagnosis of Parkinson’s disease,” Journal of Neural Transmission 2017 124:8, vol. 124, no. 8, pp. 915–964, Apr. 2017, doi: 10.1007/S00702-017-1717-8.
A. A and A. S, “Benztropine,” xPharm: The Comprehensive Pharmacology Reference, pp. 1–4, Aug. 2020, doi: 10.1016/B978-008055232-3.61299-1.
A. Boyle and W. Ondo, “Role of apomorphine in the treatment of Parkinson’s Disease,” CNS Drugs, vol. 29, no. 2, pp. 83–89, Feb. 2015, doi: 10.1007/S40263-014-0221-Z/FIGURES/2.
A. Ciobica, Z. Olteanu, M. Padurariu, and L. Hritcu, “The effects of pergolide on memory and oxidative stress in a rat model of Parkinson’s disease,” J Physiol Biochem, vol. 68, no. 1, pp. 59–69, Mar. 2012, doi: 10.1007/S13105-011-0119-X/TABLES/1.
D. Salat and E. Tolosa, “Levodopa in the Treatment of Parkinson’s Disease: Current Status and New Developments,” J Parkinsons Dis, vol. 3, no. 3, pp. 255–269, Jan. 2013, doi: 10.3233/JPD-130186.
J. Jankovic and W. Poewe, “Therapies in Parkinson’s disease,” Curr Opin Neurol, vol. 25, no. 4, pp. 433–447, Aug. 2012, doi: 10.1097/WCO.0B013E3283542FC2.
F. N. Emamzadeh and A. Surguchov, “Parkinson’s disease: Biomarkers, treatment, and risk factors,” Front Neurosci, vol. 12, no. AUG, p. 612, Aug. 2018, doi: 10.3389/FNINS.2018.00612/BIBTEX.
J. Jankovic and E. K. Tan, “Parkinson’s disease: etiopathogenesis and treatment,” J Neurol Neurosurg Psychiatry, vol. 91, no. 8, pp. 795–808, Aug. 2020, doi: 10.1136/JNNP-2019-322338.
F. Magrinelli et al., “Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation,” Parkinsons Dis, vol. 2016, 2016, doi: 10.1155/2016/9832839.
S. L. Cheong, S. Federico, G. Spalluto, K. N. Klotz, and G. Pastorin, “The current status of pharmacotherapy for the treatment of Parkinson’s disease: transition from single-target to multitarget therapy,” Drug Discov Today, vol. 24, no. 9, pp. 1769–1783, Sep. 2019, doi: 10.1016/J.DRUDIS.2019.05.003.
P. Martinez-Martin, C. Rodriguez-Blazquez, M. J. Forjaz, and M. M. Kurtis, “Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson’s Disease,” CNS Drugs, vol. 29, no. 5, pp. 397–413, May 2015, doi: 10.1007/S40263-015-0247-X/TABLES/7.
R. B. Postuma et al., “Validation of the MDS clinical diagnostic criteria for Parkinson’s disease,” Movement Disorders, vol. 33, no. 10, pp. 1601–1608, Oct. 2018, doi: 10.1002/MDS.27362.
G. J. Geurtsen et al., “Parkinson’s Disease Mild Cognitive Impairment: Application and Validation of the Criteria,” J Parkinsons Dis, vol. 4, no. 2, pp. 131–137, Jan. 2014, doi: 10.3233/JPD-130304.
L. Marsili, G. Rizzo, and C. Colosimo, “Diagnostic criteria for Parkinson’s disease: From James Parkinson to the concept of prodromal disease,” Front Neurol, vol. 9, no. MAR, p. 156, Mar. 2018, doi: 10.3389/FNEUR.2018.00156/BIBTEX.
D. Berg et al., “Changing the research criteria for the diagnosis of Parkinson’s disease: obstacles and opportunities,” Lancet Neurol, vol. 12, no. 5, pp. 514–524, May 2013, doi: 10.1016/S1474-4422(13)70047-4.
S. Heinzel et al., “Update of the MDS research criteria for prodromal Parkinson’s disease,” Movement Disorders, vol. 34, no. 10, pp. 1464–1470, Oct. 2019, doi: 10.1002/MDS.27802.
“The genetics of sporadic Parkinson’s disease - Refining the insights from genome-wide association studies.” https://www.duo.uio.no/handle/10852/48701 (accessed Feb. 19, 2023).
B. Müller, J. Assmus, K. Herlofson, J. P. Larsen, and O. B. Tysnes, “Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson’s disease,” Parkinsonism Relat Disord, vol. 19, no. 11, pp. 1027–1032, Nov. 2013, doi: 10.1016/J.PARKRELDIS.2013.07.010.
F. Sprenger and W. Poewe, “Management of motor and non-motor symptoms in parkinson’s disease,” CNS Drugs, vol. 27, no. 4, pp. 259–272, Apr. 2013, doi: 10.1007/S40263-013-0053-2/TABLES/3.
R. F. Pfeiffer, “Non-motor symptoms in Parkinson’s disease,” Parkinsonism Relat Disord, vol. 22, pp. S119–S122, Jan. 2016, doi: 10.1016/J.PARKRELDIS.2015.09.004.
C. Váradi, “Clinical Features of Parkinson’s Disease: The Evolution of Critical Symptoms,” Biology 2020, Vol. 9, Page 103, vol. 9, no. 5, p. 103, May 2020, doi: 10.3390/BIOLOGY9050103.
H. Kataoka et al., “Step Numbers and Hoehn-Yahr Stage after Six Years,” Eur Neurol, vol. 79, no. 3–4, pp. 118–124, May 2018, doi: 10.1159/000487331.
H. Kataoka, N. Tanaka, K. Saeki, T. Kiriyama, and S. Ueno, “Low Frontal Assessment Battery Score as a Risk Factor for Falling in Patients with Hoehn-Yahr Stage III Parkinson’s Disease: A 2-Year Prospective Study,” Eur Neurol, vol. 71, no. 3–4, pp. 187–192, 2014, doi: 10.1159/000355532.
C.-H. Kim, M.-Y. Kim, J.-H. Moon, and B.-O. Lim, “Effects of Hoehn-Yahr Scale on the Activation of Lower-Extremity Muscles during Walking with Parkinson’s Patients,” Korean Journal of Sport Biomechanics, vol. 24, no. 3, pp. 287–293, Sep. 2014, doi: 10.5103/KJSB.2014.24.3.287.
S. Dipasquale et al., “Physical Therapy Versus a General Exercise Programme in Patients with Hoehn Yahr Stage II Parkinson’s Disease: A Randomized Controlled Trial,” J Parkinsons Dis, vol. 7, no. 1, pp. 203–210, Jan. 2017, doi: 10.3233/JPD-161015.
P. Martinez-Martin et al., “Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS),” J Neurol, vol. 260, no. 1, pp. 228–236, Jan. 2013, doi: 10.1007/S00415-012-6624-1/TABLES/4.
P. Martínez-Martín et al., “Parkinson’s disease severity levels and MDS-Unified Parkinson’s Disease Rating Scale,” Parkinsonism Relat Disord, vol. 21, no. 1, pp. 50–54, Jan. 2015, doi: 10.1016/J.PARKRELDIS.2014.10.026.
“Exercise prescription for Parkinson’s – how the little details make BIG impacts — Personal Health.” https://www.personalhealth.ie/helpful-hints-1/exercise-prescription-for-parkinsons-how-the-little-details-make-big-impacts (accessed Feb. 19, 2023).
E. Torbey, N. A. Pachana, and N. N. W. Dissanayaka, “Depression rating scales in Parkinson’s disease: A critical review updating recent literature,” J Affect Disord, vol. 184, pp. 216–224, Sep. 2015, doi: 10.1016/J.JAD.2015.05.059.
R. Fernández de Bobadilla, J. Pagonabarraga, S. Martínez-Horta, B. Pascual-Sedano, A. Campolongo, and J. Kulisevsky, “Parkinson’s disease-cognitive rating scale: Psychometrics for mild cognitive impairment,” Movement Disorders, vol. 28, no. 10, pp. 1376–1383, Sep. 2013, doi: 10.1002/MDS.25568.
J. Kulisevsky et al., “Measuring functional impact of cognitive impairment: Validation of the Parkinson’s Disease Cognitive Functional Rating Scale,” Parkinsonism Relat Disord, vol. 19, no. 9, pp. 812–817, Sep. 2013, doi: 10.1016/J.PARKRELDIS.2013.05.007.
E. L. Proud, K. J. Miller, B. Bilney, S. Balachandran, J. L. McGinley, and M. E. Morris, “Evaluation of Measures of Upper Limb Functioning and Disability in People With Parkinson Disease: A Systematic Review,” Arch Phys Med Rehabil, vol. 96, no. 3, pp. 540-551.e1, Mar. 2015, doi: 10.1016/J.APMR.2014.09.016.
G. T. Stebbins, C. G. Goetz, D. J. Burn, J. Jankovic, T. K. Khoo, and B. C. Tilley, “How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: Comparison with the unified Parkinson’s disease rating scale,” Movement Disorders, vol. 28, no. 5, pp. 668–670, May 2013, doi: 10.1002/MDS.25383.
J. R. Williams et al., “A comparison of nine scales to detect depression in Parkinson disease,” Neurology, vol. 78, no. 13, pp. 998–1006, Mar. 2012, doi: 10.1212/WNL.0B013E31824D587F.
M. Skorvanek et al., “Global scales for cognitive screening in Parkinson’s disease: Critique and recommendations,” Movement Disorders, vol. 33, no. 2, pp. 208–218, Feb. 2018, doi: 10.1002/MDS.27233.
L. M. Shulman et al., “Disability Rating Scales in Parkinson’s Disease: Critique and Recommendations,” Movement Disorders, vol. 31, no. 10, pp. 1455–1465, Oct. 2016, doi: 10.1002/MDS.26649.
G. Mihăilescu, I. Buraga, C. Băetu, and M. Buraga, “TREATMENT OF ADVANCED PARKINSON’S DISEASE AND ASSOCIATED PSYCHIATRIC DISTURBANCES,” Farmacia, vol. 64, p. 1, 2016.
“Textbook of Movement Disorders - Google Książki.” https://books.google.pl/books?hl=pl&lr=&id=eYvgAgAAQBAJ&oi=fnd&pg=PA131&dq=parkinson+dbs+apomorphine+duodopa&ots=fDi2fTGXRF&sig=X_mMMsj5SSz8lODhcVz6c3ADm2o&redir_esc=y#v=onepage&q=parkinson%20dbs%20apomorphine%20duodopa&f=false (accessed Feb. 19, 2023).
C. Ossig and H. Reichmann, “Treatment of Parkinson’s disease in the advanced stage,” J Neural Transm, vol. 120, no. 4, pp. 523–529, Apr. 2013, doi: 10.1007/S00702-013-1008-Y/FIGURES/2.
F. M. Weaver et al., “Randomized trial of deep brain stimulation for Parkinson disease,” Neurology, vol. 79, no. 1, pp. 55–65, Jul. 2012, doi: 10.1212/WNL.0B013E31825DCDC1.
S. Little et al., “Adaptive deep brain stimulation in advanced Parkinson disease,” Ann Neurol, vol. 74, no. 3, pp. 449–457, Sep. 2013, doi: 10.1002/ANA.23951.
P. Limousin and T. Foltynie, “Long-term outcomes of deep brain stimulation in Parkinson disease,” Nature Reviews Neurology 2019 15:4, vol. 15, no. 4, pp. 234–242, Feb. 2019, doi: 10.1038/s41582-019-0145-9.
M. S. Okun, “Deep-Brain Stimulation for Parkinson’s Disease,” https://doi.org/10.1056/NEJMct1208070, vol. 367, no. 16, pp. 1529–1538, Oct. 2012, doi: 10.1056/NEJMCT1208070.
S. Kalabina, J. Belsey, D. Pivonka, B. Mohamed, C. Thomas, and B. Paterson, “Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson’s disease in patients in Scotland and Wales,” https://doi.org/10.1080/13696998.2018.1553179, vol. 22, no. 3, pp. 215–225, Mar. 2018, doi: 10.1080/13696998.2018.1553179.
S. Skodda and T. Müller, “Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson’s disease under duodopa® therapy,” J Neural Transm, vol. 120, no. 2, pp. 315–318, Feb. 2013, doi: 10.1007/S00702-012-0856-1/FIGURES/1.
R. Ciurleo et al., “Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson’s disease and their caregivers,” J Neurol, vol. 265, no. 9, pp. 2005–2014, Sep. 2018, doi: 10.1007/S00415-018-8951-3/TABLES/5.
T. Foltynie, C. Magee, C. James, G. J. M. Webster, A. J. Lees, and P. Limousin, “Impact of duodopa on quality of life in advanced parkinson’s disease: A UK case series,” Parkinsons Dis, 2013, doi: 10.1155/2013/362908.
D. Nyholm, “Duodopa® treatment for advanced Parkinson’s disease: A review of efficacy and safety,” Parkinsonism Relat Disord, vol. 18, no. 8, pp. 916–929, Sep. 2012, doi: 10.1016/J.PARKRELDIS.2012.06.022.
“Journal of Movement Disorders.” https://www.e-jmd.org/journal/Figure.php?xn=jmd-2-1-10-3.xml&id=f2-jmd-2-1-10-3&number=94&p_name=1038_94 (accessed Feb. 19, 2023).
P. Jenner and R. Katzenschlager, “Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease,” Parkinsonism Relat Disord, vol. 33, pp. S13–S21, Dec. 2016, doi: 10.1016/J.PARKRELDIS.2016.12.003.
C. Trenkwalder et al., “Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease – Clinical practice recommendations,” Parkinsonism Relat Disord, vol. 21, no. 9, pp. 1023–1030, Sep. 2015, doi: 10.1016/J.PARKRELDIS.2015.06.012.
R. Bhidayasiri, K. R. Chaudhuri, P. LeWitt, A. Martin, K. Boonpang, and T. van Laar, “Effective delivery of apomorphine in the management of parkinson disease: Practical considerations for clinicians and parkinson nurses,” Clin Neuropharmacol, vol. 38, no. 3, pp. 89–103, May 2015, doi: 10.1097/WNF.0000000000000082.
“Understanding Deep Brain Stimulation (DBS) | Brain Institute | OHSU.” https://www.ohsu.edu/brain-institute/understanding-deep-brain-stimulation-dbs (accessed Feb. 19, 2023).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Piotr Pawłowski, Karolina Ziętara, Aleksandra Orzechowska, Mateusz Pawlina, Natalia Pawełczak, Aleksander Oskroba, Cezary Stawikowski, Karolina Raksa, Ilona Kowalczyk, Bartłomiej Zielonka
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 425
Number of citations: 0